Page last updated: 2024-08-17

quinidine and Alzheimer Disease

quinidine has been researched along with Alzheimer Disease in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (9.09)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (9.09)	29.6817
2010's	9 (81.82)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bajda, M; Brus, B; Czerwińska, P; Filipek, B; Gobec, S; Malawska, B; Sałat, K; Więckowska, A; Więckowski, K	1
Bienkowski, P; Bucki, A; Gobec, S; Godyń, J; Głuch-Lutwin, M; Kazek, G; Knez, D; Kołaczkowski, M; Malawska, B; Marcinkowska, M; Mierzejewski, P; Sienkiewicz-Jarosz, H; Siwek, A; Wichur, T; Więckowska, A; Więckowski, K; Zaręba, P	1
Antonsdottir, IM; Keltz, M; Porsteinsson, AP; Smith, J	1
Wise, J	1
Cutler, AJ; D'Amico, S; Davis, CS; Doody, RS; Ledon, F; Shin, P; Siffert, J; Yonan, C	1
Ballard, C; Corbett, A	1
Newman, JC; Steinman, MA	1
Cummings, JL; Siffert, J	1
Garay, RP; Grossberg, GT	1
Drmić, S; Mimica, N; Presecki, P	1
Billig, N; Buongiorno, P	1

Reviews

2 review(s) available for quinidine and Alzheimer Disease

Article	Year
Advancements in the treatment of agitation in Alzheimer's disease. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:11 Topics: Alzheimer Disease; Cannabinoid Receptor Agonists; Cannabinoids; Citalopram; Clinical Trials, Phase III as Topic; Dextromethorphan; Drug Combinations; Humans; Psychomotor Agitation; Quinidine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2015
AVP-786 for the treatment of agitation in dementia of the Alzheimer's type. Expert opinion on investigational drugs, 2017, Volume: 26, Issue:1 Topics: Alzheimer Disease; Animals; Brain; Deuterium; Dextromethorphan; Drug Combinations; Humans; Psychomotor Agitation; Quinidine; Randomized Controlled Trials as Topic; Tissue Distribution; Treatment Outcome	2017

Article

Year

Advancements in the treatment of agitation in Alzheimer's disease.

Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:11

Topics: Alzheimer Disease; Cannabinoid Receptor Agonists; Cannabinoids; Citalopram; Clinical Trials, Phase III as Topic; Dextromethorphan; Drug Combinations; Humans; Psychomotor Agitation; Quinidine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome

2015

AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.

Expert opinion on investigational drugs, 2017, Volume: 26, Issue:1

Topics: Alzheimer Disease; Animals; Brain; Deuterium; Dextromethorphan; Drug Combinations; Humans; Psychomotor Agitation; Quinidine; Randomized Controlled Trials as Topic; Tissue Distribution; Treatment Outcome

2017

Other Studies

9 other study(ies) available for quinidine and Alzheimer Disease

Article	Year
Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo. Bioorganic & medicinal chemistry, 2015, May-15, Volume: 23, Issue:10 Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Humans; Indans; Indoles; Male; Memory; Mice; Models, Molecular; Neuroprotective Agents; Phthalimides; Piperidines; Protein Aggregates; Scopolamine; Structure-Activity Relationship	2015
Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT European journal of medicinal chemistry, 2016, Nov-29, Volume: 124 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Catalytic Domain; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Ligands; Male; Models, Molecular; Molecular Targeted Therapy; Protein Conformation; Rats; Rats, Wistar; Receptors, Serotonin	2016
Combination drug shows promise for treating agitation in patients with Alzheimer's disease. BMJ (Clinical research ed.), 2015, Sep-22, Volume: 351 Topics: Alzheimer Disease; Dextromethorphan; Female; Humans; Male; Psychomotor Agitation; Quinidine	2015
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. CNS spectrums, 2016, Volume: 21, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Dementia, Vascular; Dextromethorphan; Diarrhea; Drug Combinations; Excitatory Amino Acid Antagonists; Female; Frontotemporal Dementia; Headache; Humans; Lewy Body Disease; Male; Middle Aged; Pseudobulbar Palsy; Quinidine; Urinary Tract Infections	2016
Dextromethorphan and quinidine are suitable for off-label short-term treatment of agitation in people with Alzheimer's disease following first-line non-drug approaches. Evidence-based medicine, 2016, Volume: 21, Issue:1 Topics: Alzheimer Disease; Dextromethorphan; Female; Humans; Male; Psychomotor Agitation; Quinidine	2016
Dextromethorphan-Quinidine for Agitation in Alzheimer Disease. JAMA, 2016, Mar-15, Volume: 315, Issue:11 Topics: Alzheimer Disease; Dextromethorphan; Female; Humans; Male; Psychomotor Agitation; Quinidine	2016
Dextromethorphan-Quinidine for Agitation in Alzheimer Disease--Reply. JAMA, 2016, Mar-15, Volume: 315, Issue:11 Topics: Alzheimer Disease; Dextromethorphan; Female; Humans; Male; Psychomotor Agitation; Quinidine	2016
Involuntary emotional expression disorder in Alzheimer's disease - psychopharmacotherapy aspects. Psychiatria Danubina, 2009, Volume: 21, Issue:3 Topics: Affective Symptoms; Alzheimer Disease; Clinical Trials as Topic; Combined Modality Therapy; Croatia; Crying; Dextromethorphan; Drug Approval; Drug Combinations; Expressed Emotion; Humans; Laughter; Psychotropic Drugs; Quinidine; United States	2009
Quinidine-induced organic mental disorders. Journal of the American Geriatrics Society, 1985, Volume: 33, Issue:7 Topics: Aged; Alzheimer Disease; Depression; Diagnosis, Differential; Female; Humans; Male; Quinidine; Substance-Related Disorders	1985